In early trading on Monday, shares of Delcath Systems (DCTH) fell by 10% after the cancer drug development company reported third-quarter revenue of $20.5 million, slightly below expectations, and lowered its full-year guidance. Nonetheless, with a debt-free status and strong cash reserves, the company remains optimistic about achieving a 150% increase in treatment volume for 2024.